Analyst firms · Leerink Partners · VCYT

Leerink Partners VCYT price target and rating history

Veracyte Inc. (VCYT) · Health Care

Leerink Partners rates Veracyte Inc. (VCYT) Market Perform with a $35 price target, as of its latest action on Nov 5, 2026. It has published 4 rating actions on VCYT since July 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a VCYT price target in the last 12 months, the median target is $48. Leerink Partners's $35 is 27% below that.

Current rating
Market Perform
Price target
$35
Median target, all firms
$48
Actions on VCYT
4

Leerink Partners price target on VCYT

$60$48$3520222023202420252026
Leerink Partners price target on VCYT, each point a stated target, July 2021 to November 2026.

Every Leerink Partners rating on VCYT

How other firms rate VCYT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersMarket Perform$35Nov 5, 2026
Piper SandlerOverweight$66Jul 15, 2026
Wolfe ResearchOutperform$55Jun 2, 2026
JefferiesBuy$45Apr 13, 2026
Morgan StanleyUnderweight$48Dec 2, 2025

Questions about Leerink Partners and VCYT

What is Leerink Partners's price target for VCYT?
Leerink Partners's latest stated price target for Veracyte Inc. (VCYT) is $35, from its action on Nov 5, 2026.
What is Leerink Partners's rating on VCYT?
Leerink Partners rates VCYT Market Perform, a neutral rating, as of Nov 5, 2026.
When did Leerink Partners last change its view on VCYT?
On Nov 5, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $35.
How does Leerink Partners's VCYT target compare with other analysts?
Across 5 firms with a VCYT price target in the last 12 months, the median target is $48. Leerink Partners's $35 is 27% below that.

More VCYT rating histories

All Leerink Partners ratingsVCYT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.